Status | Study |
Recruiting |
Study Name: Study of ARQ 092 in Patients With Overgrowth Diseases and Vascular Anomalies Condition: Proteus Syndrome PIK3CA-Related Overgrowth Spectrum (PROS) Date: 2017-03-17 Interventions: Drug: ARQ 092 Subjects will receive ARQ 092 orally at the dose level and administration schedule specifi |
Completed |
Study Name: Proteus Discover in Subjects With Uncontrolled Hypertension and Type 2 Diabetes Condition: Hypertension Diabetes Mellitus, Type 2 Hypercholesterolemi Date: 2016-06-29 Interventions: Other: Proteus Discover FDA cl |
Not yet recruiting |
Study Name: Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Initial ARV Therapy Condition: HIV Date: 2016-04-05 Interventions: Device: Digital Health Feedback System This intervention u |
Enrolling by invitation |
Study Name: Dose Finding Trial of ARQ 092 in Children and Adults With Proteus Syndrome Condition: Proteus Syndrome Date: 2015-10-31 Interventions: Drug: ARQ 092 |
Recruiting |
Study Name: Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis Condition: Tuberculosis Date: 2013-10-08 Interventions: Device: Digital Health Feedback System |
Active, not recruiting |
Study Name: Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy. Condition: High Risk Proliferative Diabetic Retinopathy Date: 2013-09-10 Interventions: Procedure: Panretinal Photocoagulation (PRP) |
Withdrawn |
Study Name: Proteus Sustained Behavior Change Study Condition: Type 2 Diabetes Mellitus Date: 2011-12-28 Interventions: Device: Proteus Sustained Behavior Change system |
Completed |
Study Name: Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants Condition: Coronary Artery Disease Proteus Syndrome Date: 2011-06-08 |
Completed |
Study Name: Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients Condition: Detection Accuracy Patient Compliance Date: 2011-03-21 Interventions: Drug: ECMPS-IEM ECMPS-IEM |
Completed |
Study Name: Community - Associated Extended-spectrum Beta-lactamases (ESBL) Condition: Infection E Coli Infections Klebsiella Infections Date: 2006-08-10 |